Trial Profile
Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 09 Oct 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 09 Oct 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 17 Dec 2020 Number of arms changed from 1 to 2. Experimental Cohort 2: Nivolumab and Relatlimab added to study protocol. Allocation changed to Non-Randomized. Study design changed from Single Group Assignment to Parallel Assignment. Planned number of patients also increased.